Salt la conținut
Global sound
BiotechTV - News

BiotechTV - News

After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)

· 21 min

Note de episod

President and CEO Malte Peters summarizes the ESMO data for vopemetistat, which was in second and third line pancreatic cancer in combination with daraxonrasib, and discusses plans for a phase 3 in first line (plus the regulatory path for later lines as well). Additionally, he discusses using PRMT5 inhibition in lung cancer and GBM.

Site: podcasters.spotify.com

Live, ultima oră: 9.845 melodii pe 3.759 posturi din 123 țări

Descoperă lumea prin radio

Mai multe moduri de a descoperi (7)

Ai auzit ceva frumos? Salvează-l sau deschide-l direct în Spotify.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
RAM FM Eighties Hit RadioContinuă să asculți